Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose relapsing-remitting multiple sclerosis (a form of MS with flare-ups and periods of recovery) first started after the age of 50
- People who began their first MS treatment within 2 years of their first symptoms appearing
- People being treated with a moderately effective MS medication, such as teriflunomide, dimethyl fumarate, diroximel fumarate, glatiramer acetate, interferon beta, or peginterferon
- People being treated with a highly effective MS medication, such as fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, or cladribine
Who may not be able to join:
- People who have been diagnosed with early progressive MS (a type of MS that worsens steadily from the beginning, rather than having flare-ups)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 33 3.88.12.87.33
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time to First Clinical Inflammatory Relapse
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.